First reported by STAT
STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
From the article
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire endocrine disease specialist Crinetics Pharmaceuticals. The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex said.
Continue reading on Fierce BiotechYou might also wanna read
STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms
STAT·2d ago
STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
STAT·1d ago
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
Bars·18h ago
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
Bars·23h ago
GSK in talks to acquire Nuvalent for over $9 billion in largest deal in more than a decade
GSK is in talks to acquire biotech firm Nuvalent for more than $9 billion, which would be its largest acquisition in over a decade and the s
cnbc.com·29d ago
STAT+: Compass says depression drug has long-lasting benefits
STAT·1d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.